oxetanocin G

08/01/1989 - "Efficacy of oxetanocin G against herpes simplex virus type 2 and murine cytomegalovirus infections in mice."
12/01/1990 - "The results indicate that OXT-G was more potent and selective against GPCMV infection than DHPG."
12/01/1990 - "Antiviral effect of oxetanocin G against guinea pig cytomegalovirus infection in vitro and in vivo."
01/01/1994 - "Although further study of the toxicity of this compound would be essential before studies in man can be carried out, OXT-G has potent antiviral activity against WHV and may deserve evaluation as an antiviral agent in the treatment of chronic hepatitis B infections in humans."
07/01/1988 - "The synthesis of HCMV-induced late polypeptides such as the 150,000-molecular-weight capsid and the 68,000-molecular-weight major matrix proteins was strongly suppressed when OXT-G (5 micrograms/ml) was added to the cultures at the beginning of infection. "

01/01/1994 - "Although further study of the toxicity of this compound would be essential before studies in man can be carried out, OXT-G has potent antiviral activity against WHV and may deserve evaluation as an antiviral agent in the treatment of chronic hepatitis B infections in humans."

04/30/1991 - "In this study we synthesized the triphosphate form of OXT-G, OXT-GTP, and examined its effect on the activities of HCMV DNA polymerase, herpes simplex type 2 (HSV-2) DNA polymerase and human DNA polymerase alpha. "

09/01/1992 - "Mouse alpha interferon (200,000 U per injection, twice daily for 3 days) and a novel nucleoside, oxetanocin G (15 mg/kg of body weight per injection, twice daily for 7 days), inhibited viral DNA synthesis in the liver almost completely. "